Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...
SAN DIEGO, May 28, 2026--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced that the first ...
STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors Overall, 262 patients with ER+/HER2– ...
In a recent study published in the journal Pharmacological Research, researchers investigated the synergistic efficacy of two glycemic control drugs – dapagliflozin and semaglutide. They carried out ...
A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that ...
CHICAGO — Levothyroxine (LT4) monotherapy remains the standard treatment for hypothyroidism, although a subset of patients continue to have hypothyroidism despite normal thyroid-stimulating hormone ...
Combination therapy is essentially a one-two punch at cancer—sometimes with multiple punches. For people with lung cancer, it means treating a tumor with more than one type of therapy at the same time ...
A Clinical-Stage Molecule Drives Selective In Vivo Expansion of Tumor-Specific T Cells, Achieving 100% Survival in a High Tumor Burden Ovarian Cancer Model and Promoting Strong Tumor Infiltration in a ...
Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan; hereinafter "Kowa"), today announced that on June 11, it received Breakthrough ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results